Companies
Daiichi Sankyo
Delivery platforms — Vector engineering.
- Country
- Japan
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | 2,123.0 billion JPY for FY2025 | daiichisankyo.com |
| Headcount | 20,171 employees globally (as of March 31, 2026) | daiichisankyo.com |
| Production site | 13 production sites globally | daiichisankyo.com |
| Funding | Approximately 300 billion JPY ($1.9 billion) committed to global ADC manufacturing expansions as of early 2026 | fiercepharma.com · pharmamanufacturing.com |
| Capacity | Biologics manufacturing platforms utilize CHO cell gene expression systems demonstrating up to 10g/L productivity medium confidence | daiichisankyo.com |
Independent sources: fiercepharma.com · pharmamanufacturing.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Antibody-drug conjugates (ADCs) | therapeutics-platforms | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.